Nuformix PLC (NFX)
Industry Biotechnology
This stock can be held in an Investment ISA, SIPP and Investment Account
Sell
0.25p
Buy
0.28p
0.055p (+26.19%)
Prices updated at 12 Dec 2025, 16:30 GMT
| Prices minimum 15 mins delay
Prices in GBX
Nuformix PLC is a pharmaceutical development company using cocrystal technology to unlock the therapeutic potential of approved drugs with lead programmes in oncology supportive care and fibrosis.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Profit margins
Valuation
Profit margins data table
Year | Gross margin (%) |
|---|---|
| 2024 | - |
| 2022 | 96.61 |
| 2021 | 68.14 |
| 2020 | 37.65 |
| 2019 | 11.88 |
| 2018 | -1,259.12 |
Valuation data table
Year | Price / Sales |
|---|---|
| 2025 | - |
| 2024 | - |
| 2023 | - |
| 2022 | - |
| 2021 | 135.74 |
| 2020 | 67.44 |
| 2019 | 77.63 |
| 2018 | 20.46 |
| 2017 | - |
| 2016 | - |
Price/Forward earnings (YTD)
-
Returns
Debt profile
Returns data table
Year | Return on assets (%) |
|---|---|
| 2024 | -135.16 |
| 2022 | -20.19 |
| 2021 | -22.51 |
| 2020 | -15.50 |
| 2019 | -34.39 |
| 2018 | -72.85 |
Debt profile data table
| Year | Financial leverage |
|---|---|
| 2024 | 1.36 |
| 2022 | 1.05 |
| 2021 | 1.06 |
| 2020 | 1.08 |
| 2019 | 1.21 |
| 2018 | 1.12 |
The figures shown in the Profit Margins table EBITDA column are quoted in the currency of the stock selected.
